New eye scan could spot drug damage before vision fades
NCT ID NCT07409740
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will use a non-invasive eye scan called OCTA to look for tiny blood vessel changes in the retina of 90 adults who have taken hydroxychloroquine for at least a year. Hydroxychloroquine, used for autoimmune diseases, can sometimes harm the retina with long-term use. The goal is to see if OCTA can detect early signs of damage, which could help doctors monitor patients more closely and prevent vision loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to better screening methods to catch hydroxychloroquine-related eye damage early, helping prevent vision loss.
What could go wrong
This is an observational study, not a treatment trial. It may not change current monitoring practices, and results might not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYDROXYCHLOROQUINE RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.